AGC Inc.
5201・Prime Market・Glass & Ceramics Products
Business
AGC Inc., founded in 1907, is a comprehensive materials manufacturer with five reportable segments: Architectural Glass, Automotive, Electronics, Chemicals, and Life Science. Including 192 subsidiaries and 26 affiliates, the group's consolidated net sales totaled ¥2,058,832 million (FY2025). The company supplies foundational materials and components to a wide range of industries worldwide, spanning Flat Glass for Architecture, Glass Substrates for LCD Displays, Photomask Blanks for EUV Lithography, fluorochemicals, and Biopharmaceutical CDMO. It maintains production facilities across multiple regions, including Europe, Asia, and South America, establishing a geographically diversified business foundation.
Business Model
The company adopts a "dual-track management" approach, generating stable cash flow from core businesses (Architectural Glass, Automotive, Chemicals) while pursuing high profitability and high growth in strategic businesses such as Electronic Materials and Life Science. It places ROCE improvement through pricing policy, product mix optimization, and productivity gains at the center of business management, with stable dividends targeting a DOE of approximately 3% as its basic shareholder return policy. Having completed the large-scale investment phase through FY2025 (ending March 2025), from FY2026 (ending March 2026) onward the company will shift its focus toward maximizing utilization of existing facilities and recovering investment returns.
Company Strengths
The company holds a high market share in components for semiconductor front-end processes, including Photomask Blanks for EUV Lithography and CMP slurry. The Electronics segment's operating margin stands at 13.4%, the highest level among all segments. By integrally holding inorganic and organic materials together with functional design and processing technologies, the company has built a product lineup that is difficult for competitors to imitate.
The company operates production sites across Europe (Belgium, Germany, etc.), Southeast Asia (Thailand, Indonesia), South America (Brazil), North America, China, and other regions worldwide. Since entering Europe in 1981, it has continued regional expansion through M&A, building a diversified portfolio that reduces dependence on any specific region.
The fluorochemicals business, launched in 1964, has developed into Performance Chemicals encompassing fluoropolymer resins, gases, and solvents for electronics, energy, and mobility applications. The Chemicals segment as a whole secured operating profit of ¥53,035 million (operating margin of 9.1%), making it the largest profit-contributing segment within the group.
ENVALITH's Perspective
Performance Trend
Revenue had remained flat in the low ¥2,000,000 million range following the FY2021 peak, but accelerated in Q1 FY2026 (ending December 2026) to ¥537,965 million (+7.7% year on year). Operating profit had stagnated at low levels since peaking at ¥206,168 million in FY2021, but improved significantly in Q1 FY2026 to ¥38,472 million (+48.9% year on year). The main factors were the disappearance of the foreign exchange loss (¥6,310 million) recorded in the same period of the previous year, the turnaround to profitability in Architectural Glass (from -¥934 million to ¥4,675 million), and increased profit in Chemicals (from ¥11,085 million to ¥15,224 million). The full-year forecast remains unchanged at revenue of ¥2,200,000 million (+6.9% year on year) and operating profit of ¥150,000 million (+17.7% year on year). Quarterly net income attributable to owners of the parent reached ¥22,844 million, 3.4 times the level of the same period of the previous year (¥6,645 million), and basic quarterly net income per share was ¥107.73 (compared with ¥31.35 in the same period of the previous year).
Growth Strategy
Aiming for ROE above 8% through three pillars: ROCE improvement, expansion of semiconductor-related businesses, and profitability turnaround in Life Science
Promoting expanded sales of Photomask Blanks for EUV Lithography in advanced fields and new development of packaging-related components for semiconductor back-end processes. Benefiting from the external tailwind of expanding AI-related investment, operating profit for the Electronics segment in 1Q FY2026 (ending March 2026) was maintained at ¥12,265 million (operating margin of 13.7%).
Promoting fixed cost reductions through the operation of expanded facilities for the Synthetic Pharmaceutical & Agrochemical CDMO business, increased orders for the Biopharmaceutical CDMO business, and closure of the Colorado site in the United States. Operating loss in 1Q FY2026 (ending March 2026) improved to ¥3,324 million from ¥6,156 million in the same period of the previous year, but profitability has not yet been achieved.
Promoting maintenance of pricing policies in Europe and the United States, response to demand recovery in Asia, and expanded sales of highly insulating products such as Low-E multi-layer glass. In 1Q FY2026 (ending March 2026), the Architectural Glass segment achieved a turnaround to operating profit of ¥4,675 million, compared to an operating loss of ¥934 million in the same period of the previous year.
Promoting expanded shipments of caustic soda to Indonesia through the full-scale operation of expanded facilities at Essential Chemicals Southeast Asia, and increased shipments of fluorine-related products by Integrated Chemicals. Operating profit in 1Q FY2026 (ending March 2026) increased significantly to ¥15,224 million, up from ¥11,085 million in the same period of the previous year.
Last updated: July 17, 2026